Dr. Jerel A. Banks M.D., Ph.D. Net Worth

Dr. Jerel A. Banks M.D., Ph.D. biography

Dr. Jerel A. Banks M.D., Ph.D. is the CEO & Exec. Chairman at Benitec Biopharma Inc.

What is the salary of Dr D?

As the CEO & Exec. Chairman of Benitec Biopharma Inc, the total compensation of Dr D at Benitec Biopharma Inc is $697,688. There are no executives at Benitec Biopharma Inc getting paid more.

How old is Dr D?

Dr D is 46, he's been the CEO & Exec. Chairman of Benitec Biopharma Inc since . There are 1 older and no younger executives at Benitec Biopharma Inc. The oldest executive at Benitec Biopharma Inc is Megan Joan Boston BComm, CA, Dip., GAICD, 49, who is the Exec. Director.

What's Dr D's mailing address?

Jerel's mailing address filed with the SEC is C/O BENITEC BIOPHARMA INC., 3940 TRUST WAY, HAYWARD, CA, 94545.

Insiders trading at Benitec Biopharma Inc

Over the last 4 years, insiders at Benitec Biopharma Inc have traded over $0 worth of Benitec Biopharma Inc stock and bought 409,597 units worth $1,496,765 . The most active insiders traders include Steven Michael Oliveira, J Kevin Buchi a Edward F Smith. On average, Benitec Biopharma Inc executives and independent directors trade stock every 278 days with the average trade being worth of $1,152,330. The most recent stock trade was executed by J Kevin Buchi on 11 August 2023, trading 51,813 units of BNTC stock currently worth $437,302.

What does Benitec Biopharma Inc do?

benitec biopharma is using patented ‘gene-silencing’ technology to develop drugs for chronic and life-threatening human diseases. our transformational technology, ddrnai, targets and ‘turns off’ specific genes related to disease, providing lasting treatment and potentially cure with a single dose. compared to traditional approaches to rna intereference, ddrnai is easier to deliver, safer to us, more targeted and more efficient. benitec has a pipeline of in-house and partnered drug development programs based on ddrnai, including hepatitis c and b and cancer-associated pain. ddrnai has the potential to silence genes related to thousands of human diseases and is protected by over 40 global patents. the technology is available from benitec under a variety of licence options.

Benitec Biopharma Inc executives and stock owners

Benitec Biopharma Inc executives and other stock owners filed with the SEC include:

• Dr. Jerel A. Banks M.D., Ph.D.,
  CEO & Exec. Chairman
• Megan Joan Boston BComm, CA, Dip., GAICD,
  Exec. Director
• Dr. Claudia Kloth,
  Sr. VP of Manufacturing
• Dr. Craig Lewis,
  Chief Medical Adviser
• Dr. Michael Graham,
  Head of Discovery & Founding Scientist
• Bryan Dulhunty,
  Chief Financial Officer
• Edward F Smith,
  Director
• Megan Boston,
  Executive Director
• Jerel A. Banks,
  Chief Executive Officer
• Peter Francis,
  Director
• Steven Michael Oliveira,
  10% owner
• J Kevin Buchi,
  Director